Refine by
Phase 1 Clinical Suppliers In Germany
9 companies found
based inMunich, GERMANY
multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform for the development and clinical delivery of new cancer therapies on the basis of the founding scientists' ...
ENKASTIM-ev is an innovative product candidate representing a new class of therapy known as Active Cellular Immunotherapies (ACIs). ACI is a treatment approach which capitalizes on the power of vital human cells to re-engage the patient's own ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
based inBasel, SWITZERLAND
We are a Biologics CDMO (Contract Development and Manufacturing Organization) offering our clients more than just development and manufacturing. In everything we do, we go one step beyond expectations. We enable our customers to exceed their goals ...
based inBerlin, GERMANY
MerLion Pharmaceuticals is a biopharma company focusing on the research and development of drugs for the treatment of serious bacterial infections. MerLion - located in Berlin-Buch, Germany - manages the non-clinical and clinical development as well ...
based inRavensburg, GERMANY
Vetter is an international specialist in the production of aseptically prefilled syringe systems, cartridges and vials. We are a family-owned, independent company and do not manufacture our own drugs. Our focus is on providing highly skilled support ...
Explore how we transform your API into a supply of high-quality clinical material for your ...
based inTübingen, GERMANY
Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company ...
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral diseases: COVID-19 and influenza, two ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inBerlin, GERMANY
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We ...
based inMunich, GERMANY
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic ...